The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes PatientsReport as inadecuate




The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients - Download this document for free, or read online. Document in PDF available to download.

International Journal of Endocrinology - Volume 2016 2016, Article ID 4350712, 7 pages -

Research Article

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China

Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China

Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, China

Changsha Medical University Teaching Hospital, The People’s Hospital of Liuyang, Liuyang 410300, China

Received 29 September 2015; Revised 2 January 2016; Accepted 6 January 2016

Academic Editor: Franco Veglio

Copyright © 2016 Di Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. We aimed to investigate the distributive characteristics of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients. Methods. The distributions of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms were determined in 267 T2DM patients and 182 healthy subjects. Subsequently, 53 newly diagnosed patients who received metformin monotherapy were recruited to evaluate metformin efficacy. Results. No significant difference was found between T2DM patients and healthy subjects in SLC22A1 rs594709 and SLC47A1 rs2289669 allele frequencies and genotype frequencies. After metformin treatment, SLC22A1 rs594709 GG genotype patients showed a higher increase in FINS and decrease in HOMA-IS and QUICKI than A allele carriers. SLC47A1 rs2289669 GG genotype patients had a higher decrease in TChol and LDL-C than A allele carriers. Among SLC22A1 rs594709 AA genotype, patients with SLC47A1 rs2289669 AA genotype showed a higher decrease in FBG , PINS , and HOMA-IR than G allele carriers. However, among SLC22A1 rs594709 G allele carriers, SLC47A1 rs2289669 AA genotype patients showed a higher decrease in TChol than G allele carriers. Conclusion. Our data suggest that SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms may influence metformin efficacy together in Chinese T2DM patients.





Author: Di Xiao, Yu Guo, Xi Li, Ji-Ye Yin, Wei Zheng, Xin-Wen Qiu, Ling Xiao, Rang-Ru Liu, Sai-Ying Wang, Wei-Jing Gong, Hong-Ha

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents